ESG Report 2025

The Group also actively participates in the national healthcare system reform, further improving the affordability of medicines in the Chinese market by being included in the National Medical Insurance Drug List and the national volume-based procurement (VBP) of drugs. A total of 71 products of the Group have been included in the National Medical Insurance Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2024 Edition), of which 26 are Category A and 45 are Category B. In addition, a total of 32 products of the Group have been included in the National Essential Medicines List (2018 Edition). The Group actively responds to national policy calls and participates voluntarily in the national volume-based drug procurement. To alleviate the long-term medication burden on diabetic patients in China, the National Healthcare Security Administration organised a national volume-based drug procurement (special renewal for insulin), with the procurement period from May 2024 to December 2027. This round of procurement covers the insulin needs of medical institutions nationwide, with a total demand exceeding 240 million units, and the price of selected products decreased by an additional 3.8% compared with the first round. All of the Group's insulin products were successfully selected in this round of procurement. Taking this as an opportunity, we will continue to enhance the accessibility of insulin products, strive to expand market share, and effectively reduce the economic burden on diabetic patients, so that more patients can benefit. The Group will continue to align with the direction of national healthcare reform, enabling more patients to access high-quality treatment at more affordable prices through the volume-based procurement channel, thereby fulfilling the corporate commitment to improving drug accessibility. 8.2.3 Enhancement of Healthcare Standards Improving healthcare standards is not only about providing high-quality medicines, but also about promoting the dissemination of medical knowledge and capacity-building in medical technology. The United Laboratories continuously provides professional training for primary healthcare workers at home, while also assisting overseas customers in upgrading their pharmaceutical technology standards, thereby supporting the development of global healthcare from multiple perspectives. The Group, adhering to its mission of “To Make Life More Valuable”, attaches great importance to public health and fully supports the provisions of the “Doha Declaration on the TRIPS Agreement and Public Health” concerning the protection of public health and the granting of compulsory licences for patents in emergency situations. As a manufacturer of generic drugs, the Group is also committed to promoting fair competition in the generic drug market, providing the public with more affordable and high-quality drug options. In terms of healthcare professional training, the Group actively facilitates pharmaceutical academic exchange and information dissemination. During the Reporting Period, the Group participated in 22 large-scale academic conferences, with a cumulative attendance of over 2,500 participants, including the Annual Meeting of the Diabetes Professional Committee of the Chinese Research Hospital Association, the Conference of the Diabetes and Endocrinology Professional Committee of the Chinese Medical Women's Association, and the Academic Conference on Diabetes Education and Management of the Chinese Medical Association. “Dual Action Initiative” – Primary Diabetes Prevention and Management Training Programme 62 The nationwide public welfare training programme – the “Dual Action Initiative” Primary Diabetes Prevention and Management Training Course, jointly launched by The United Laboratories and the Diabetes Professional Committee of the Chinese Research Hospital Association – continues to be implemented. Since its launch in 2019, this programme has been held for seven consecutive years, with over 110 training sessions cumulatively delivered, covering more than 50 provinces, municipalities, and regions nationwide, and providing training to over 80,000 person-times of primary- level diabetes physicians. By inviting renowned domestic diabetes experts to deliver lectures and share the latest clinical guidelines and experience, the programme aims to enhance the diagnostic and treatment capabilities of primary doctors for diabetes and their ability to use medicines rationally, contributing to improving the quality of primary diabetes prevention and treatment and supporting the implementation of tiered healthcare. The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report